Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Company's Board of Directors has appointed biopharmaceutical leader Corinne Le Goff, Pharm D, MBA, as President and Chief Executive Officer and Director, effective July 18, 2022. Current President and CEO Michael H. Tardugno will continue to serve as Executive Chairman of Celsion's Board of Directors. Dr. Le Goff brings decades of global healthcare leadership experience to the Company across a range of therapeutic areas i

With this important addition to its executive team, Science 37 will further advance its mission to accelerate clinical trials by enabling universal access to patients and providers Science 37, pioneer of the Decentralized Clinical Trial Operating System™ (DCT OS), today announced that Christine Pellizzari has joined the senior executive team as Chief Legal Officer. In this role, Ms. Pellizzari will use her nearly 30 years of legal expertise to manage the legal and quality functions to help advance Science 37's mission to enable universal access to clinical research for patients and providers, anywhere. This press release features multimedia. View the full release here: https://www.business

Brings extensive biopharmaceutical legal background to the Board Appointment increases the size of Celsion’s Board from seven to eight Directors LAWRENCEVILLE, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the appointment of Christine A. Pellizzari to the Celsion Board of Directors, effective June 8, 2021. Ms. Pellizzari is Chief Legal Officer of Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases and brings to Celsion more than 20 years of leadership i

Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the formation of a Vaccine Advisory Board and the appointment of its first two members: Britt A. Glaunsinger, Ph.D., Professor, Virology & Molecular Biology, Howard Hughes Medical Institute, University of California, Berkeley, and Dr. Xinzhen Yang, M.D., Ph.D., Independent Professional Consultant for the Gerson Lehman Group and former Director of Viral Vaccines / Program Lead of the HCMV Vaccine Program at

4 - Imunon, Inc. (0000749647) (Issuer)

3 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

New name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company's business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's common stock will trade on the Nasdaq Stock Market under the new ticker symbol "IMNN" effective as of the opening of trading on September 21, 2022. The Company has filed an amendmen

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment with 110 patients. GEN-1 is the Company's IL-12 gene-mediated immunotherapy. Topline results are expected in the second half of 2023. The OVATION 2 Study combines GEN-1 with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with S

LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time. The presentation will available live and on-demand here. As previously announced, the conference will be held September 12-14 with in-person participation at the Lotte New York Palace Hotel. Dr. Le Goff is also available for in-person meetings at the conference. About Celsion Corporation Celsion is a fully integrated, clinical-stage biotechnol

LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will be held from September 12-14 with in-person participation held at the Lotte New York Palace Hotel. Dr. Le Goff will present in person on Tuesday, September 13th at 4:00 pm ET. A replay of the presentation will available under "Financial Events" in the Investors section of the Company's website at: https://investor.c

PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the development of a DNA-based vaccine using its PLACCINE platform technology. Additional data from its completed proof-of-concept mouse challenge study confirms that a PLACCINE vaccine can produce robust levels of IgG, neutralizing antibodies, and T-cell responses. The Company previously reported evidence of IgG, neutralizing antibody, and T-cell responses to its SARS-CoV-2 PLACCINE vac

DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three and six months ended June 30, 2022, and provided an update on its clinical development program of GEN-1, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase II clinical development for the treatment of advanced-stage ovarian cancer, and its preclinical studies of PLACCI

LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss financial results for the second quarter ended June 30, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologie

LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 177,000 shares of common stock, and (ii) restricted stock grants (the "Inducement Stock Grants") totaling 53,000 shares of common stock to Corinne Le Goff, the Company's new President and Chief Executive Officer, effective July 18, 2022. The Inducement Option Grants have an exercise price per share equal to $1.95, the clos

Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Company's Board of Directors has appointed biopharmaceutical leader Corinne Le Goff, Pharm D, MBA, as President and Chief Executive Officer and Director, effective July 18, 2022. Current President and CEO Michael H. Tardugno will continue to serve as Executive Chairman of Celsion's Board of Directors. Dr. Le Goff brings decades of global healthcare leadership experience to the Company across a range of therapeutic areas i

Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit Full Enrollment Expected by Third Quarter of 2022 LAWRENCEVILLE, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that following a pre-planned interim safety review of 87 as treated patients (46 patients in the experimental arm and 41 patients in the control arm) randomized in the Phase I/II OVATION 2 Study with GEN-1 in advanced (Stage III/IV) ovarian cancer, the Data Safety Monitoring Board (DSMB) has unanimously recommended that the OVATION 2 Study continue treating

SC 13G/A - Celsion CORP (0000749647) (Subject)

SC 13G/A - Celsion CORP (0000749647) (Subject)

SC 13G - Celsion CORP (0000749647) (Subject)

LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss financial results for the second quarter ended June 30, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologie

LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, May 16, 2022 to discuss financial results for the first quarter ended March 31, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies fo

LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 31, 2022 to discuss financial results for the year ended December 31, 2021 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies fo

Balance Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug-development company focused on DNA-based immunotherapy and next-generation vaccines, today announced financial results for the three and nine months ended September 30, 2021, and provided an update on clinical development programs with GEN-1, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase II clinical development for the treatment of advanced-stage ovarian cancer (Stage III/IV), and ThermoDox®, a proprietary heat-activated

LAWRENCEVILLE, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, November 15, 2021 to discuss financial results for third quarter ended September 30, 2021 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technolog

LAWRENCEVILLE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. EDT on Thursday, August 12, 2021 to discuss financial results for the second quarter ended June 30, 2021 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technolo

Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company's business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's common stock will trade on the Nasdaq Stock Market under the new ticker symbol "IMNN" effective as of the opening of trading on September 21, 2022. The Company has filed an amendment to its Articles of Incorporation to effect the new corporate name and is introducing a new logo and a new corporate website, www.imunon.com. Imunon is establishing a leadership po

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7 to $46.29 on day volume of 15.14 million shares, closed regular trading session at $45.94. Alnylam (NASDAQ: ALNY) and Regeneron (NASDAQ: REGN) announced preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatit

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment with 110 patients. GEN-1 is the Company's IL-12 gene-mediated immunotherapy. Topline results are expected in the second half of 2023. The OVATION 2 Study combines GEN-1 with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with Sta

According to Benzinga Pro data, during Q2, Celsion (NASDAQ:CLSN) posted sales of $125 thousand. Earnings were up 42.31%, but Celsion still reported an overall loss of $6.04 million. Celsion collected $125 thousand in revenue during Q1, but reported earnings showed a $10.47 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Celsion post

PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the development of a DNA-based vaccine using its PLACCINE platform technology. Additional data from its completed proof-of-concept mouse challenge study confirms that a PLACCINE vaccine can produce robust levels of IgG, neutralizing antibodies, and T-cell responses. The Company previously reported evidence of IgG, neutralizing antibody, and T-cell responses to its SARS-CoV-2 PLACCINE vaccines

Celsion (NASDAQ:CLSN) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.12) by 22.32 percent. This is a 3.33 percent increase over losses of $(0.90) per share from the same period last year. The company reported quarterly sales of $125.00 thousand which beat the analyst consensus estimate of $80.00 thousand by 56.25 percent. This is the same as the same period last year.

  Celsion (NASDAQ:CLSN) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Celsion beat estimated earnings by 22.32%, reporting an EPS of $-0.87 versus an estimate of $-1.12. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.83 which was followed by a 1.56% increase in the share price the next day.   To track all earnings releases for Celsion visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.

  Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. • GreenPower Motor Co (NASDAQ:GP) is estimated to report quarterly loss at $0.15 per share on revenue of $5.59 million. • Mondee Hldgs (NASDAQ:MOND) is likely to report quarterly loss at $0.04 per share on revenue of $38.94 million. • Reshape Lifesciences (NASDAQ:RSLS) is expected to report quarterly loss at $0.35 per share on revenue of $3.41 million. • Alaunos Therapeutics (NASDAQ:TCRT) is expected to report earnings for its second quarter. • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $0.19 per share on revenue of $5.25 million. • IM Cannab

  Celsion (NASDAQ:CLSN) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement. Analysts estimate that Celsion will report an earnings per share (EPS) of $-1.12. Celsion bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company missed EPS by $0.83, which was followed by a 1.56% increase in the sha